Rat experimental groups comprised ex vivo liver samples of wild type, NAFLD, LAL-deficient, and LAL-deficient rats receiving 4 weeks of sebelipase alfa treatment. This evidence concerns the gene LIPA and metabolic dysfunction-associated steatotic liver disease.